PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVincristine
Vincristine
Vincristine (vincristine) is a small molecule pharmaceutical. Vincristine was first approved as Oncovin on 1982-01-01. It is used to treat hodgkin disease, leukemia, neuroblastoma, non-hodgkin lymphoma, and rhabdomyosarcoma amongst others in the USA. The pharmaceutical is active against tubulin beta chain.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
immune system diseasesD007154
Trade Name
FDA
EMA
Vincristine (discontinued: Marqibo, Oncovin, Vincasar, Vincrex, Vincristine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vincristine sulfate
Tradename
Company
Number
Date
Products
MARQIBO KITAcrotech BiopharmaN-202497 DISCN2012-08-09
1 products, RLD
ONCOVINEli LillyN-014103 DISCN1982-01-01
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
vincristine sulfateANDA2026-02-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
leukemia—D007938C95
non-hodgkin lymphoma—D008228C85.9
neuroblastomaEFO_0000621D009447—
hodgkin disease—D006689C81
rhabdomyosarcoma—D012208—
wilms tumorEFO_0000212D009396—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CA: Vinca alkaloids and analogues, antineoplastic
— L01CA02: Vincristine
HCPCS
Code
Description
J9370
Vincristine sulfate, 1 mg
J9371
Injection, vincristine sulfate liposome, 1 mg
Clinical
Clinical Trials
1397 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.91083291401834573
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.058138662323276
Large b-cell lymphoma diffuseD016403—C83.3571435459233
LeukemiaD007938—C9545115541517220
Non-hodgkin lymphomaD008228—C85.94910655710202
B-cell lymphomaD016393——561023468174
Lymphoid leukemiaD007945—C91266830169138
Follicular lymphomaD008224—C821934332380
SarcomaD012509——1139161972
Burkitt lymphomaD002051—C83.72140132—69
Show 27 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeuroblastomaD009447EFO_0000621—182416—460
Central nervous system neoplasmsD016543——92215—549
Ewing sarcomaD012512EFO_0000173—8256—438
RhabdomyosarcomaD012208——72011—234
Nervous system neoplasmsD009423——41611—434
Multiple myelomaD009101—C90.051413—131
RecurrenceD012008——14124—229
Precursor t-cell lymphoblastic leukemia-lymphomaD054218——9196——27
Plasma cell neoplasmsD054219——31011—125
Brain neoplasmsD001932EFO_0003833C716106—223
Show 70 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Plasmablastic lymphomaD000069293—C83.376———11
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—37———9
Aids-related lymphomaD016483EFO_1001365—36———9
Acute diseaseD000208——53———8
SyndromeD013577——36———8
Hematologic neoplasmsD019337——42——27
Blast crisisD001752——16———7
Adult t-cell leukemia-lymphomaD015459—C91.533———5
Myeloid leukemia chronic-phaseD015466——13———4
T-cell lymphoma cutaneousD016410—C84.A22——14
Show 76 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PinealomaD010871——2———13
Sezary syndromeD012751—C84.11———12
Mycosis fungoidesD009182—C84.01———12
Myelodysplastic-myeloproliferative diseasesD054437——2————2
HypersensitivityD006967EFO_0003785T78.401————1
Deltaretrovirus infectionsD006800EFO_1001303—1————1
Htlv-i infectionsD015490EFO_0007316—1————1
Composite lymphomaD058617——1————1
Rectal neoplasmsD012004——1————1
MycosesD009181—B35-B491————1
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G20————66
VomitingD014839—R11.1————33
NauseaD009325—R11.0————33
ConstipationD003248—K59.0————22
Cognitive dysfunctionD060825—G31.84————11
Non-small-cell lung carcinomaD002289——————11
AtaxiaD001259—R27.0————11
Ataxia telangiectasiaD001260Orphanet_100G11.3————11
TelangiectasisD013684——————11
Cerebellar ataxiaD002524——————11
Show 33 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVincristine
INNvincristine
Description
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Classification
Small molecule
Drug classvinca alkaloids
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Identifiers
PDB—
CAS-ID57-22-7
RxCUI—
ChEMBL IDCHEMBL90555
ChEBI ID28445
PubChem CID5978
DrugBankDB00541
UNII ID5J49Q6B70F (ChemIDplus, GSRS)
Target
Agency Approved
TUBB
TUBB
Organism
Homo sapiens
Gene name
TUBB
Gene synonyms
TUBB5
NCBI Gene ID
203068
Protein name
tubulin beta chain
Protein synonyms
beta Ib tubulin, epididymis secretory sperm binding protein, tubulin beta-1 chain, Tubulin beta-5 chain, tubulin, beta polypeptide
Uniprot ID
Q9CY33
Mouse ortholog
Tubb5 (22154)
tubulin beta-5 chain (Q3UF52)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Marqibo – Spectrum Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Vincristine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vincristine sulfate
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
93,131 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use